BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Andersen RL, Johnson DJ, Patel JN. Personalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathways. Pharmacogenomics 2016;17:417-34. [PMID: 26871520 DOI: 10.2217/pgs.15.178] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Patel JN, Boselli D, Hamadeh IS, Symanowski J, Edwards R, Susi B, Greiner R, Baldassare D, Waller M, Wodarski S, Turner S, Slaughter C, Edelen C. Pain Management Using Clinical Pharmacy Assessments With and Without Pharmacogenomics in an Oncology Palliative Medicine Clinic. JCO Oncology Practice 2020;16:e166-74. [DOI: 10.1200/jop.19.00206] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
2 Kasi PM, Koep T, Schnettler E, Shahjehan F, Kamatham V, Baldeo C, Hughes CL. Feasibility of Integrating Panel-Based Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With Colorectal Cancer. Technol Cancer Res Treat 2019;18:1533033819873924. [PMID: 31533552 DOI: 10.1177/1533033819873924] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
3 Patel JN, Boselli D, Jandrisevits EJ, Hamadeh IS, Salem A, Meadors P, Walsh D. Potentially actionable pharmacogenetic variants and symptom control medications in oncology. Support Care Cancer 2021;29:5927-34. [PMID: 33758969 DOI: 10.1007/s00520-021-06170-4] [Reference Citation Analysis]
4 Patel JN, Arnall J, Jandrisevits E, Morse AL, Steuerwald N, Copelan E, Walsh D. Pharmacogenomics-guided supportive oncology: A tale of two trials. Contemp Clin Trials 2021;105:106391. [PMID: 33819640 DOI: 10.1016/j.cct.2021.106391] [Reference Citation Analysis]
5 Patel JN, Wiebe LA, Dunnenberger HM, McLeod HL. Value of Supportive Care Pharmacogenomics in Oncology Practice. Oncologist 2018;23:956-64. [PMID: 29622698 DOI: 10.1634/theoncologist.2017-0599] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
6 Vieira CMP, Fragoso RM, Pereira D, Medeiros R. Pain polymorphisms and opioids: An evidence based review. Mol Med Rep 2019;19:1423-34. [PMID: 30592275 DOI: 10.3892/mmr.2018.9792] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
7 Bell GC, Caudle KE, Whirl-Carrillo M, Gordon RJ, Hikino K, Prows CA, Gaedigk A, Agundez J, Sadhasivam S, Klein TE, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther 2017;102:213-8. [PMID: 28002639 DOI: 10.1002/cpt.598] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 16.6] [Reference Citation Analysis]
8 Ta R, Cayabyab MA, Coloso R. Precision medicine: a call for increased pharmacogenomic education. Per Med 2019;16:233-45. [PMID: 31025601 DOI: 10.2217/pme-2018-0107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Gilmore J, D'Amato S, Griffith N, Schwartzberg L. Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists. Cancer Manag Res 2018;10:1827-57. [PMID: 30013391 DOI: 10.2147/CMAR.S166912] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
10 Miller MG, Kneuss TG, Patel JN, Parala-Metz AG, Haggstrom DE. Identifying potentially inappropriate medication (PIM) use in geriatric oncology. J Geriatr Oncol 2021;12:34-40. [PMID: 32571665 DOI: 10.1016/j.jgo.2020.06.013] [Reference Citation Analysis]